Acute Myelogenous Leukemia
-25 %

Acute Myelogenous Leukemia

Besorgungstitel | Lieferzeit:3-5 Tage I

Unser bisheriger Preis:ORGPRICE: 275,50 €

Jetzt 207,14 €*

Alle Preise inkl. MwSt. | zzgl. Versand
Judith E. Karp
826 g
254x178x mm
Contemporary Hematology

Novel therapeutic concepts based on AML cell biology Critical factors in leukemia cell survival and drug resistance, and their potential exploitation as therapeutic targets
TABLE OF CONTENTSI. Overview of AML: Francis Giles, MD Anderson
II. Molecular Foundations of AML Pathogenesis and Pathophysiology
A. Transcriptional Control of Myeloid Differentiation and Transformation: Alan Friedman, Johns Hopkins
B. Myelodysplasia-Related AML: Ghulam Mufti, King's College, London, England
C. Treatment-Related AML: Michelle LeBeau, University of Chicago
D. DNA Damage and Repair: David Steensma and Scott Kaufmann Mayo Clinic
E. Apoptosis: Ruben Mesa and Scott Kaufmann, Mayo Clinic
F. Drug Resistance Transporters: Douglas Ross, University of Maryland
III. Translating Biology into Clinical Application
A. Impact of Cytogenetics on Clinical Outcome: David Grimwade, Guy's Hospital, London, England
B. APL: A Classic Tale of Bench to Bedside: Martin Tallman, Northwestern
C. Molecular Therapeutics of AML: Selected Targeted Approaches
Overview: Edward Sausville, University of Maryland
FLT3: Mark Levis, Johns Hopkins
Farnesyltransferase: Jeffrey Lancet, Moffitt (University of South Florida)
Modulating Gene Expression as a Therapeutic Approach: Tamer Fandy,
Hetty Carraway, Steven Gore, Johns Hopkins
Growth Factor-Based Differentiation: William Matsui, Johns Hopkins
D. Stem Cell Transplantation: Richard Jones, Johns Hopkins
E. Vaccine Development: Ivan Borrello, Johns Hopkins
IV. Special Challenges
A. Pediatric AML: Robert Arceci, Johns Hopkins -- pending
B. AML in the Elderly: Richard Stone, Dana Farber
C. Myeloproliferative Disorders: Jason Gottlib, Stanford
D. New Clinical Trials Designs: Elihu Estey, MD Anderson
This is a timely compilation of new concepts in the molecular pathogenesis and molecular therapy of acute myelogenous leukemia (AML). The focus is on selected critical molecular determinants of AML pathogenesis and pathophysiology and the exploitation of these factors by diverse therapeutic agents and modalities. There is an emphasis throughout on the bidirectional flow of knowledge between the clinical and laboratory arenas.